Aptorum Group Limited Announces Pricing of Initial Public Offering

HONG KONG–(BUSINESS WIRE)–Aptorum Group Limited (“Aptorum”, or the “Company”), a Hong Kong based
pharmaceutical company currently in the preclinical stage, dedicated to
developing and commercializing therapeutic projects and diagnostic
technologies to tackle unmet medical needs, today announced that on
December 3, 2018, its registration statement on Form F-1, relating to a
proposed initial public offering (“IPO” or the “Offering”) of its Class
A Ordinary Shares, par value US$1.00 per share (the “Shares”), at a
price to the public of $15.80 per share, for gross proceeds of a minimum
of US$10 million and up to US$30 million, has been declared effective by
the U.S. Securities and Exchange Commission (“SEC”). The Company is
offering up to 1,898,734 Shares and up to 51,990 underwriter warrants
while certain selling shareholders are offering up to 1,595,235 Shares
(collectively, the “Registered Securities”). None of the gross proceeds
will be used to purchase the selling shareholders’ securities. The
Shares are expected to begin trading on The NASDAQ Global Market
on December 18, 2018, under the symbol APM. This Offering is expected to
close on or before December 12, 2018, subject to customary closing
conditions.

The Offering will be sold on a best-efforts basis. Boustead Securities,
LLC, China Renaissance Securities (HK) Limited, and AMTD Global Markets
Limited are acting as Co-Underwriters for the Offering.

As stated above, a registration statement relating to the Registered
Securities (File No.: 333-227198) has been filed with the SEC and was
declared effective on December 3, 2018. The Offering is made only by
means of a written prospectus forming part of the effective registration
statement. A copy of the prospectus may be obtained for free by visiting
EDGAR on the SEC’s website at www.sec.gov.
Alternatively, copies of the prospectus relating to this Offering may be
obtained from: Boustead Securities, LLC, email: offerings@boustead1828.com
or by calling +1 (949) 502-4409 or standard mail at Boustead Securities,
LLC, Attn: Equity Capital Markets, 6 Venture, Suite 265, Irvine, CA
92618, USA. This press release shall not constitute an offer to sell, or
the solicitation of an offer to buy any of the Company’s securities, nor
shall such securities be offered or sold in the United States absent
registration or an applicable exemption from registration, nor shall
there be any sale of such securities in any state or jurisdiction in
which such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.

About Aptorum Group Limited

We are a Hong Kong based pharmaceutical company currently in the
preclinical stage, dedicated to developing and commercializing a broad
range of therapeutic and diagnostic technologies to tackle unmet medical
needs. We have obtained exclusive licenses for our technologies. In
addition, we are also developing certain proprietary technologies as
product candidates. We are pursuing therapeutic and diagnostic projects
(including projects seeking to use extracts or derivatives from natural
substances to treat diseases) in neurology, infectious diseases,
gastroenterology, oncology and other disease areas. We also have
projects focused on surgical robotics. In addition, we opened a medical
clinic, AML Clinic, in June 2018. Its initial focus is on treatment of
chronic diseases resulting from modern sedentary lifestyles and aging
population. For more information about the Company, please visit www.aptorumgroup.com.

About Boustead Securities, LLC

Boustead Securities, LLC (“Boustead”) is an investment banking firm that
executes and advises on IPOs, mergers and acquisitions, capital raises
and restructuring assignments in a wide array of industries, geographies
and transactions, for a broad client base. Boustead’s core value
proposition is the ability to create opportunity through innovative
solutions and tenacious execution. With experienced professionals in the
United States and around the world, Boustead’s team moves quickly and
provides a broad spectrum of sophisticated financial advice and
services. For more information, visit www.boustead1828.com.

About China Renaissance Securities (Hong Kong) Limited

China Renaissance (“CR”) is a leading financial institution that
combines private placement advisory, M&A advisory, securities
underwriting, research, sales and trading, investment management and
other financial services. Providing one-stop financial services across
mainland China, Hong Kong and the United States, CR operates a
competitive and unique international network that connects China’s
capital markets with the rest of the world, serving new economy
entrepreneurs and investors globally. CR has offices in Beijing,
Shanghai, Hong Kong and New York, with approximately 600 employees. As
of March 31, 2018, CR had advised on approximately 700 transactions
worth over US$100 billion since the inception, and CR had AUM of
approximately US$4.1 billion in new economy investments. For more
information, visit www.huaxing.com.

About AMTD Global Markets Limited

AMTD Global Markets Limited (“AMTD”) is a Hong Kong-based comprehensive
financial institution dedicated to serving and bridging capital and
resources across mainland China, Hong Kong and the globe. As one of the
largest Hong Kong-based non-bank financial institution, AMTD has been
widely recognized as a pre-eminent capital markets player with leading
cross-border investment banking capabilities in Asia. Founded in 2003,
AMTD has a long history of promoting technological innovations and the
development of New Economy sectors, especially in the fields of FinTech,
Artificial Intelligence and Healthcare. For more information, visit www.amtdgroup.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements concerning plans, objectives, goals,
strategies, future events or performance, and underlying assumptions and
other statements that are other than statements of historical facts.
When the Company uses words such as “may, “will, “intend,” “should,”
“believe,” “expect,” “anticipate,” “project,” “estimate” or similar
expressions that do not relate solely to historical matters, it is
making forward-looking statements. Specifically, the Company’s
statements regarding listing on the NASDAQ Global Market and the
completion of the IPO are forward-looking statements. Forward-looking
statements are not guarantee of future performance and involve risks and
uncertainties that may cause the actual results to differ materially
from the Company’s expectations discussed in the forward-looking
statements. These statements are subject to uncertainties and risks
including, but not limited to, risks and uncertainties related to the
satisfaction of the customary closing conditions related to the IPO and
the listing on NASDAQ . For these reasons, among others, investors are
cautioned not to place undue reliance upon any forward-looking
statements in this press release. Additional factors are discussed in
the Company’s filings with the U.S. Securities and Exchange Commission,
which are available for review at 
www.sec.gov.
The Company undertakes no obligation to publicly revise these
forward‐looking statements to reflect events or circumstances that arise
after the date hereof unless required by the applicable laws,
regulations or rules.

Contacts

For more information, please contact:
At the Company:
Sabrina
Khan, CFO
Aptorum Group Limited
Phone: +852 2117 6611
Email: investor.relations@aptorumgroup.com